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Background: Chronic kidney disease is a common complication after liver trans-
plantation. In this study, we analyzed the results of kidney biopsy in liver transplan-
tation recipients with renal impairment.
Methods: Between 1999 and 2012, 544 liver transplants were performed at our
hospital. We retrospectively analyzed the clinical and histological data of 10 liver
transplantation recipients referred for kidney biopsy.
Results: The biopsies were performed at a median of 24.5 months (range, 3–73
months) after liver transplantation. The serum creatinine level was 1.8170.5 mg/dL at
the time of kidney biopsy. There were no immediate complications. The most common
diagnosis was glomerulonephritis (GN), such as immunoglobulin A nephropathy (n¼4),
mesangial proliferative GN (n¼1), focal proliferative GN (n¼1), and membranous GN
(n¼1). Typical calcineurin inhibitor (CNI)-induced nephrotoxicity was detected in three
cases (30%). Chronic tissue changes such as glomerulosclerosis, interstitial ﬁbrosis, and
tubular atrophy were present in 90%, 80%, and 80% of cases, respectively, and mesangial
proliferation was detected in 40% of cases. We began treatment for renal impairment
based on the result of kidney biopsy; for example, angiotensin-receptor blockers or
steroids were prescribed for GN, and the CNI dosewas reduced for CNI nephrotoxicity. As
a result, eight of 10 patients showed improvement in glomerular ﬁltration rate, but two
progressed to end-stage renal disease.
Conclusion: Kidney biopsy is a safe and effective method for determining the cause of
renal impairment after liver transplantation. Management of patients based on the result
of kidney biopsy may improve renal outcomes.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).n Society of Nephrology. Publi
c-nd/4.0/).
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ung).Introduction
Renal impairment is a commonly detected problem after
liver transplantation (LT), and the cumulative incidence of
chronic kidney disease (CKD) in liver transplant recipients is
estimated at 18.1% at 5 years [1]. Proper management of renalshed by Elsevier. This is an open access article under the CC BY-NC-ND
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of the renal injury has been clearly identiﬁed. In this regard,
kidney biopsy is a very important instrument for determining
the cause of renal impairment and deciding on the appropriate
management plan in liver transplant recipients.
However, until now, only a few reports have used kidney
biopsies to investigate the cause of renal impairment, and
these studies have had contradictory results. For example, some
reports have suggested that calcineurin inhibitor (CNI)-induced
nephrotoxicity is the main cause of renal impairment [2–5]. By
contrast, other recent reports proposed that kidney pathology
after LT is variable and not limited to CNI toxicity [6–8]. In
addition, the main cause of hepatic failure in Korea is hepatitis
B, which is signiﬁcantly different from that in the Western
population where hepatitis C plays the main role [5,9–11].
Considering that the cause of the chronic liver disease may
affect the pathology of renal disease, the renal histology in liver
transplant recipients with renal impairment in Korea may have
a different pattern than that in the Western population, as
reported previously [7,8,12].
For these reasons, we analyzed the results of kidney
biopsies in liver transplant recipients with renal impairment
and investigated whether kidney biopsy is useful for guiding
the management of renal impairment.Table 1. Patients characteristics at the time of kidney biopsy
Value
Gender (male) 10 (100)
Mean age at Kidney biopsy 50.378.2
Duration between LT and
Kidney Bx (mo)
24.5725.4
Origin of liver disease
HBV 8 (80)
HCV 0 (0)
Alcoholic liver cirrhosis 1 (10)
portal vein thrombosis 1 (10)
Diabetes mellitus 7 (70)
Hypertension 2 (20)
HCC 3 (30)
AST(U/L) 32.4721.7
ALT(U/L) 54.1758
Platelet (109/L) 192.17109
INR 1.0570.13
Immunosuppresive treatment
Tacrolimus 8 (80)
Cyclosporine 2 (20)
Tacrolimus level(ng/mL) 5.3171.5
Cyclosporine level(ng/mL) 189.4764.5
Serum Creatinine(mg/dL) 1.870.5
eGFR by MDRD(mL/min/1.73m2) 42.2713.9
24hr urine protein(g/day) 6.3710.1
Proteinuria 4 3g/day 3 (30)
Proteinuria o 3g/day 7 (70)
Data are presented as mean ± SD or n (%).Methods
Patient group
Between 1999 and 2012, 544 liver transplants were performed
at our center. In this study, we included 10 patients who under-
went kidney biopsy because of unexplained increase of serum
creatinine (n¼6), newly developed proteinuria [41 g protein/g
creatinine (g/g) in random spot urine; n¼2], and proteinuria
(40.5 g/g) accompanied with microscopic hematuria (n¼2).
Clinical and histological data were extracted from the patients'
electronic medical records. We reviewed several variables, includ-
ing each patient's demographic data, laboratory ﬁndings, medica-
tion history, and the ﬁndings of the kidney biopsy. Renal function
was assessed by calculating the estimated glomerular ﬁltration
rate (eGFR) using themodiﬁcation of diet in renal disease equation
[13]. The amount of proteinuria was quantiﬁed with a 24-hour
urine collection at the time of biopsy. This study was approved by
the Institutional Review Board of our institution (KC13RISI0327).
Biopsy procedure
All patients underwent standard percutaneous biopsies per-
formed by experienced nephrologists under ultrasound guidance,
using an automatic spring-loaded core biopsy system. Biopsy
specimens were collected for light microscopy (hematoxylin–
eosin, periodic acid–Schiff, silver methenamine, and trichrome
staining), immunoﬂuorescence, and electron microscopy. All biop-
sies were reviewed by a single experienced renal pathologist at our
institution. Morphologic entities were deﬁned by standard criteria.
Statistical analysis
Continuous variables are presented as median and interquartile
range or mean7standard deviation. The results were considered
signiﬁcant when Po0.05. Statistical analysis was performed using
the SPSS version 11.5 (SPSS Inc., Chicago, IL, USA).Results
Baseline characteristics of the patient population
The baseline characteristics of the study participants are
summarized in Table 1. The most common primary liver
disease was hepatitis B (n¼8); there was one case each of
alcoholic liver cirrhosis and portal vein thrombosis. In three
patients, hepatocellular carcinoma was combined prior to LT. In
all patients, liver function was stable, according to the results of
liver function tests, platelet counts, prothrombin international
normalized ratio, and albumin level. The main immunosup-
pressive drug used was tacrolimus in eight patients, and
cyclosporine (CsA) was used in two patients. In nine patients,
diabetes mellitus was combined, and in two of these patients,
diabetes mellitus developed after LT.
Renal manifestations in the patient population
Kidney biopsy was performed at 24.5 months (3–66
months) after LT, and the mean age at biopsy was 50.378.2
years. The indications for biopsy were elevated serum creati-
nine (Scr) level in six cases, proteinuria in two cases, and
proteinuria with hematuria in two cases. At the time of biopsy,
Scr level was 1.870.5 mg/dL, and eGFR was 42.2713.9 mL/min/
1.73 m2. The 24-hour urine protein excretion was 6.3710.1 g/
day, and nephrotic-range proteinuria was found in three patients.
Drug concentrations (trough level) were 5.371.5 ng/mL in the
eight patients using tacrolimus and 189.4764.5 ng/mL in the
two patients using cyclosporine (Table 1). After kidney biopsy,
there were no immediate complications.
Histologic ﬁndings of kidney biopsy
Histopathological ﬁndings are summarized in Table 2. All
biopsy specimens were adequate for diagnosis, and the number
Table 2. Histopathologic ﬁndings
Case Light microscopyn Immunoﬂuorescence
GGS/GI MM GBMt GNE Int.F TA AS AH ATN SpLe
1 1/4 þþ N N þþ þþ N N N IgA, CIN IgA, IgM, C3
2 1/11 N N N þþ þþ þ N N CPN IgG, IgA, IgM, C3, κ, λ
3 2/18 þþþþ N N þþ þþ N N N IgA IgA, IgG, IgM, C3, κ, λ
4 0/14 þ N N þþ þþ þþ N N IgA, Arteriosclerosis IgA, IgM, C4d, C1q, κ, λ
5 0/7 N N N N N N N N CIN IgG, IgA, C4d
6 0/8 þþþ N N N N þþþ N N MsPGN N/A
7 1/5 þþ N N þþ þþ þ þþþ N FPGN, CIN IgG, IgA, IgM, C3, κ, λ
8 1/12 þ þþþ N þ þ N N N MGN IgA, Ig, C1q
9 5/8 þþ N N þþþ þþþ þ þþþ N Arteriosclerosis, DN IgG, IgM
10 16/28 þþ N N þþþ þþþ þþ N N IgA IgA, IgM,C3, κ, λ
n Affected degree: N, nonspeciﬁc ﬁnding; þ , o20%; þþ , 20–40%; þþþ , 40–70%; þþþþ , 4 70%.
AH, arterial hyalinosis; AS, arteriosclerosis; ATN, acute tubular necrosis; CIN, calcineurin inhibitor nephrotoxicity; CPN, chronic pyelonephritis; DN,
diabetic nephropathy; FPGN, focal proliferative glomerulonephritis; GBMt, glomerular basement membrane thickening; GGS, global glomerulo-
sclerosis; GI, glomeruli; GNE, glomerularnodular expansion; Int.F, interstitial ﬁbrosis; IgA, immunoglobulin A nephropathy; MGN, membranous
glomerulonephritis; MM, mesangial matrix proliferation; MsPGN, mesangial proliferative glomerulonephritis; N/A, not applicable; SpLe, speciﬁc
histological lesions; TA, tubular atrophy.
Table 3. Clinical outcomes after kidney biopsy
Case Age/
Gender
Cause
of LD
HTN DM Indication
of KB
Time from LT
to KB (mo)
SCr at KB Immuno-
suppresion
at KB
Pathologic
diagnosis
SCr at
last f/u
Renal
replacement
therapy
1 32/M CHB   SCr ↑ 4 2.08 TK IgA, CIN 1.49 –
2 61/M PVT  þ SCr ↑ 12 2.75 TKþMMF CPN 1.2 –
3 45/M CHB   SCr ↑ 21 1.67 TK IgA 1.05 –
4 54/M CHB  þ Prot/H 13 1.84 CsA IgA,
arteriosclerosis
1.45 –
5 46/M CHB  þ SCr ↑ 73 1.8 TKþMMFþST CIN 1 –
6 49/M CHB   Prot/H 4 1.05 TKþMMFþST MsPGN 0.88 –
7 56/M CHB þ þ SCr ↑ 16 2.27 TKþMMFþST FPGN,CIN 7.9 + (HD)
8 49/M CHB  þ Prot 3 1.09 CsA MGN 1.19 –
9 40/M CHB þ þ Prot 66 1.7 CsAþST DN,
arteriosclerosis
11.42 + (PD)
10 51/M ALC  þ SCr ↑ 33 1.8 TK IgA 2.15 –
ALC, alcoholic liver cirrhosis; CHB, chronic hepatitis B; CsA, cyclosporine; CIN, calcineurin inhibitor nephrotoxicity; CPN, chronic pyelonephritis; DM,
diabetes mellitus; DN, diabetic nephropathy; FPGN, focal proliferative glomerulonephritis; H, hematuria; HD, hemodialysis; HTN, hypertension; IgA,
immunoglobulin A nephropathy; KB, kidney biopsy; LD, liver disease; LT, liver transplantation; MGN, membranous glomerulonephritis; MMF,
mycophenolic acid; MsPGN, mesangial proliferative glomerulonephritis; PD, peritoneal dialysis; PVT, portal vein thrombosis; Prot, proteinuria; SCr ↑,
serum creatinine elevation; ST, steroid; TK, tacrolimus.
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In most patients, chronic change was detected; the ﬁndings
included glomerulosclerosis in 90% (9/10), global glomerulo-
sclerosis in 70% (7/10), interstitial ﬁbrosis in 80% (8/10), tubular
atrophy in 80% (8/10), and vascular ﬁbrous wall thickening in 60%
(6/10). Additionally, mesangial cell proliferation was found
in 40% (4/10). In seven out of 10 patients, GN was diagnosed;
immunoglobulin A nephropathy (IgAN) was the most
common diagnosis (n¼4), followed by mesangial proliferative
GN (n¼1), focal proliferative GN (FPGN; n¼1), and membranous
GN (MGN; n¼1). In the remaining two cases, there was
chronic pyelonephritis (PN) and diabetic nephropathy, respec-
tively. Out of the 10 patients, typical CNI nephrotoxicity was
observed in three. Electron microscopy was performed in three
patients who were diagnosed with IgAN (n¼2) and chronic PN
(n¼1). In the two patients with IgAN, podocyte foot process
effacement was observed, and in the patient with chronic PN,
immune complex deposits were seen in the mesangial basement
membranes.Clinical outcome after kidney biopsy
Table 3 depicts the clinical outcome after kidney biopsy
during the follow-up period of 47.1 months (range, 6–112
months). Based on the result of kidney biopsy, we began
speciﬁc therapy for each patient. In the four patients who
were diagnosed with IgAN, we started angiotensin-receptor
blockers. In the two patients with nephrotic proteinuria,
who were ultimately diagnosed with FPGN or MGN, we used
steroid therapy with prednisolone (1 mg/kg). In the patient
with chronic PN, we initiated antibiotic therapy. In the three
patients with CNI nephrotoxicity, we reduced the dose of
calcineurin inhibitor by 20%. After treatment, Scr level showed
improvement in eight cases (1.7670.54 mg/dL at biopsy vs.
1.3670.54 mg/dL at last follow-up; P¼0.062). However, renal
impairment did not improve and progressed to end-stage
renal disease in two cases after 6 months and 35 months
each. These patients (Cases 7 and 9) required hemodialysis and
peritoneal dialysis.
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In liver transplant recipients, many risk factors, such as the
progression of underlying renal disease, hemodynamic factors
during the operation, metabolic problems, and nephrotoxic
agents, can lead to the deterioration of renal function [14,15].
Proper management of renal impairment in liver transplant
recipients is important because the development of CKD in liver
transplant recipients is a major risk factor for patient mortality
[16]. In this study, we analyzed the various histopathological
diagnoses from kidney biopsies performed in liver transplant
recipients, and we found that kidney biopsy is useful for
determining the possible etiology of the renal impairment and,
even more, for suggesting a speciﬁc management plan for liver
transplant recipients.
The most characteristic ﬁnding in the renal histology of
this study population was chronic renal tissue injury rather
than acute inﬂammation. Global glomerulosclerosis was found
in 70% (7/10) of biopsies, and the sclerosis percentage of the
total glomeruli was 19.3730.0%. Tubulointerstitial ﬁbrosis
worse than Grade 2 was detected in 70% of biopsies. In
patients with advanced liver disease, a signiﬁcant portion of
them showed advanced CKD as shown previously [17]. In
addition, CNI may aggravate the progression of CKD. Hence,
we thought that both pre-existing renal lesion and post-
transplant change are associated with the chronic kidney
lesion in those patients.
By contrast, acute lesions, such as mesangial proliferation
and interstitial inﬁltration, are relatively less common. The Scr
level at biopsy was only 1.870.5 mg/L, and 18% of patients had
a normal Scr level at the time of biopsy, which suggests that
even though a decrease in renal function might not be
apparent, histologic ﬁndings may show advanced tissue injury
in liver transplant recipients.
The most common histologic diagnosis in this study was GN
(n¼7) and six GN patients were infected with hepatitis B virus
(HBV). It is well known that some types of GN, especially
membranous GN, show signiﬁcant association with HBV infec-
tion [18]. However, three of six cases of GN infected with HBV
were IgAN, whose association with HBV infection has not been
established in previous reports [19,20]. Thus, the large number
of IgAN cases in this study may accidently result from a high
prevalence of IgAN in Korean society [21]. Another possible
reason is that patients with underlying IgAN may be more
vulnerable to kidney injury after liver transplantation. How-
ever, this issue could not be clariﬁed due to the limited case
number of this study.
The prevalence of CNI nephrotoxicity was lower in this
study than in previous reports [5,22,23]. Indeed, typical CNI
nephrotoxicity was found in 30% of cases (3/10), and it
appeared to be the main cause of renal impairment in only
one case. However, this result does not underestimate the
importance of CNI nephrotoxicity, which has been emphasized
in many previous reports [5,22,23]. The possible reason for the
lower incidence of CNI nephrotoxicity is that the time from the
LT to the kidney biopsy was relatively short, and, even more,
the CNI level had been kept low in most patients. Thus,
another renal disease may have caused the renal impairment
prior to when typical chronic CNI nephrotoxicity developed.
We decided on the appropriate management plan based on
the histologic diagnosis; for example, angiotensin-receptor
blockers were prescribed for IgAN, steroid pulse therapy for
MGN or mesangial proliferative GN, antibiotics for chronic PN,and dose reduction was used in patients with CNI nephrotoxi-
city. After the initiation of treatment, improvement of renal
function occurred in eight out of 10 patients. In patients with
CNI nephrotoxicity there was marked improvement; a signiﬁ-
cant decrease in the Scr level was found within several weeks
of the reduction in the CNI dose. These ﬁndings suggest that, in
many cases, speciﬁc therapy based on the results of kidney
biopsy can delay or reverse the progression of CKD.
Meanwhile, two patients did not respond to therapy
and progressed to end-stage renal disease. One patient had
end-stage diabetic nephropathy on kidney biopsy and
another patient had FPGN with massive proteinuria, which
did not respond to steroid pulse therapy. The common
ﬁndings of the above patients were advanced chronic injury
or massive proteinuria, compared with the other patients with
more favorable clinical outcomes. It suggests that early per-
formance of kidney biopsy and aggressive management of
liver transplant recipients may be help delay the progression
of CKD.
The safety of kidney biopsy is an important issue as well.
Even though many liver transplant recipients have the indica-
tions for kidney biopsy, only a limited number of cases have
been referred for this procedure, possibly because of concerns
about bleeding in liver transplant recipients [7]. We checked
the laboratory tests associated with excessive bleeding, such as
platelet count and activated partial thromboplastin time, and
decided to perform the kidney biopsy when the results were
within the normal range; as a result, we had no complications
secondary to bleeding in this study. Therefore, we suggest that
careful examination of the liver function and bleeding ten-
dency is necessary prior to kidney biopsy to avoid serious
complication related to it.
The limitation of this study is the small sample size. Only 2%
of total liver transplant recipients in our center underwent
kidney biopsy for the evaluation of renal impairment. Con-
sidering that about two-thirds of liver transplant recipients
suffer chronic kidney injury, an analysis performed on a larger
study population may be warranted.
Nevertheless, this study showed that kidney biopsy is safe
and useful for diagnosing various patterns of renal disease that
are not limited to CNI nephrotoxicity. Moreover, our results
suggest that a kidney biopsy may help to determine the
speciﬁc management plans required to improve renal impair-
ment in liver transplant recipients.Conﬂict of interest
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